SmithKline shares fall on Avandia blow; EU panel fails to approve antidiabetes drug
Article Abstract:
SmithKline Beecham PLC's shares fell almost 12% after a panel advising the EU's main drug regulator rejected an application for Avandia, the company's antidiabetes medicine. The regulatory action took took precedence over a 14% increase in third-quarter net income and an optimistic prediction by Chief Executive Jan Leschly that the drugmaker is on track to make its full-year goal of 13% per-share earnings growth.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Powderject's shares decline by 16%
Article Abstract:
Powderject Pharmaceuticals PLC saw its share value decline by 16%. The drop in share value, to 830 pence per share, came after the company said that it would postpone the launch of a main product.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Genmab admirers should examine some relationships
Article Abstract:
The article discusses Genmab A.S.' intentions to raise as much as 2.1 billion kroner (Euro281.5 million) through its IPO, which could become the largest-ever biotech IPO in Europe.
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2000
User Contributions:
Comment about this article or add new information about this topic: